1Dworkin RH, Backonja M, Rowhotham MC, et al. Advances inneurepthic pain : diagnosis, mechanisms, and treatment recommendations. Arch Neu- ro1,2003,60 : 1524-1534.
2Sills GJ. Themechanisms of action ofgahapentin and pregabalin. Curr Opin Pharmaco1,2006,6 : 108-113.
3Bian F,Li Z,Offord J,et al. Calcium channel alpha-deltatype 1 subunit is themajorbinding protein forpregabalin in neocortex, hippocampus, amygdala,and spinal cord: an exvivo autoradiographic study in alpha-delta type 1 genetically modifiedmice. Brain Res ,2006,1075:68-80.
4DE Moulin, AJ Clark, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the ca- nadian pain society. Pain Res ,2007,12 : 13-21.
5Jones D, SorKin L. Systemic gabapentin and S ( + )-3-isobutyl-:-ami- nobutyric acid block secondary hrperalgesla. Brain Res, 1998,810 : 93- 99.
